Open AccessCDK12 and HER2 coamplification in two urothelial carcinomas with rapid and aggressive clinical progression
Author(s) -
Yanai Yoshinori,
Kosaka Takeo,
Nakamura Kohei,
Aimono Eriko,
Matsumoto Kazuhiro,
Morita Shinya,
Mikami Shuji,
Nishihara Hiroshi,
Oya Mototsugu
Publication year - 2020
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.14672
Subject(s) - cancer research , epidermal growth factor receptor , medicine , tyrosine kinase , carcinoma , receptor tyrosine kinase , urothelial carcinoma , cancer , pathology , biology , oncology , receptor , bladder cancer
Cyclin‐dependent kinase 12 ( CDK12 ), one of the key factors associated with DNA damage response pathways, is located on chromosome 17 proximal to Erb‐B2 receptor tyrosine kinase 2 ( ERBB2 ). In this report, CDK12 and ERBB2 coamplification was detected by targeted next‐generation sequencing in two urothelial carcinomas. The staining intensity of the CDK12 and human epidermal growth factor receptor‐2 proteins was associated with the prognosis of each urothelial carcinoma case. Our results suggest that CDK12 coamplification with ERBB2 might be associated with tumor aggressiveness and contribution to cancer pathogenesis. Therapies targeting CDK12 should be developed for these patients.